SGX Market Updates

Trio of SGX Rubber Glove Makers Report Earnings Surge


PUBLISHED ON |

03 September 2020

  • SGX lists 3 rubber glove plays – Top Glove Corp, Riverstone Holdings and UG Healthcare Corp.

  • Global demand for gloves is expected to increase as countries step up efforts to contain the spread of COVID-19. The Malaysian Rubber Glove Manufacturers Association (MARGMA) forecasts global rubber glove demand to increase 11% to 330 billion pieces in 2020.

  • Due to the exponential increase in glove demand, the three rubber glove makers reported stellar results for their respective financial periods, with earnings surging as much as five-fold. The trio are also planning production capacity increases to alleviate the current supply crunch.




SGX lists 3 rubber glove plays – Top Glove Corp, Riverstone Holdings and UG Healthcare Corp


Top Glove (SGX:BVA): The world’s largest manufacturer of gloves is primary-listed on the Bursa Malaysia, with a secondary listing on SGX. It produces 78.7 billion gloves annually for more than 2,000 customers worldwide and exports to more than 195 countries. Meanwhile Top Glove Corp Bhd has moved from being outside the top 120 Asia Pacific Healthcare stocks by market value to within the top 30, in addition to now ranking as ASEAN’s biggest healthcare stock by market value. 


Riverstone (SGX:AP4): With an annual production capacity of about 9.0 billion gloves, it makes premium nitrile gloves used in the healthcare industry, as well as nitrile and natural rubber clean room gloves. 


UG Healthcare (SGX:41A): Manufactures and sells disposable gloves under its proprietary “Unigloves” brand through an established global downstream distribution network. It also distributes other medical disposables, such as surgical gloves, vinyl and cleanroom disposable gloves, and face masks. 



Robust Industry Prospects 

Global demand for gloves is expected to increase as countries step up efforts to contain the spread of COVID-19. The Malaysian Rubber Glove Manufacturers Association (MARGMA) forecasts global rubber glove demand to increase 11% to 330 billion pieces this year, with 67% of the demand set to be fulfilled by local glove makers, according to local media reports. 



Top Glove Corporation (3Q ended 31 May 2020)

  • Revenue reached a record of RM1.7 billion, up 42% y-o-y, while profit before tax increased 413% to RM422 million, and profit after tax jumped 365% to RM350 million.
  • Monthly sales orders surged 180%, resulting in lead times rising to around 400 days from 40 days.
  • Following the marked increase in glove demand from virtually every country in the world, the Group’s utilisation rate rose from a pre-COVID level of 85% to above 95% in 3Q FY2020, resulting in greater efficiency and economies of scale.

TOP GLOVE (RM'000) 3QFY2020 3QFY2019 YoY Chg
(%)
Revenue 1,688,324 1,190,235 41.9
Profit from operations 429,879 104,169 312.7
Profit before tax 422,020 82,239 413.2
Profit net of tax 350,033 75,188 365.5

Source: Company data 



Riverstone Holdings (1H ended 30 June 2020)

  • Revenue rose 30.5% y-o-y to RM626.7 million, following the surge in global demand for products such as healthcare examination gloves, clean room gloves and face masks.
  • Gross profit jumped 108.4% y-o-y to RM197.7 million, while attributable net profit increased 119.3% to RM137.5 million.
  • As a result, blended gross profit margin expanded 11.8 percentage points y-o-y to 31.6%.

RIVERSTONE (RM mln) 1H2020 1H2019 YoY Chg
(%)
Revenue 626.7 480.3 30.5
Gross profit 197.7 94.9 108.4
Profit before tax 175.2 74.2 136.3
Net profit 137.5 62.7 119.3

Source: Company data 



UG Healthcare (FY ended 30 June 2020)

  • The Group achieved record revenue of S$144.2 million and net profit of S$13.4 million for the financial year.
  • This was due to increased volumes of glove products produced and sold, with contribution from new production lines, as well as higher selling prices amidst the COVID-19 outbreak.

UG HEALTHCARE (S$'000) FY2020 FY2019 YoY Chg
(%)
Revenue 144,209 91,712 57.2
Gross profit 42,519 18,716 127.2
Profit before tax 18,057 2,763 553.5
Profit net of tax 13,402 2,507 434.6

Source: Company data 



Outlook


Top Glove Corporation (SGX:BVA)
  • Top Glove will continue to expand its capacity to ensure it is well-positioned to fulfil global glove demand, which is expected to grow from a pre-COVID level of 8%-10% per annum to 12%-15% per annum. This is on the back of increased usage in both the medical and non-medical sectors, as well as heightened hygiene awareness.
  • Top Glove has earmarked RM3 billion for capex to build 450 new lines, creating new capacity of 60 billion pieces of gloves from CY2020 to CY2026.
  • The Group’s blueprints for expansion up to CY2022 are illustrated in the table below:

Top Glove's Factories and Production Plan

  • The Top Glove Innovation Complex (TGIC) at Factory 42 in Banting is the Group’s new manufacturing and research centre - 
    • A smart and digitalised manufacturing plant, it leverages Industry 4.0 technology, big data analytics for optimum productivity and process efficiency, aimed at reducing dependency on manual labour for routine/repetitive tasks.
    • It represents a pivotal shift to Industry 4.0 connecting the Group’s factories together, which all future factories will be modelled after.
    • Phase 1 of the TGIC is expected to be completed by 2Q CY2022.
  • Top Glove expects extremely robust quarters ahead, driven by strong demand growth, high utilisation and additional capacity coming onstream, coupled with a continued focus on innovation, technology, quality and cost efficiency.
  • With a year's worth of orders in the pipeline, Top Glove is confident of delivering solid results not only for the full FY2020, but for FY2021 as well.
  • Top Glove is expected to release its FY20 (ending 31 August) results by the end of September, after reporting the Group's 9MFY20 Sales Revenue was RM 4.1 billion, a 14% y-o-y increase, while Profit After Tax was RM 577.8 million, a 97% y-o-y increase, which had also exceeded the net profits for the full financial year 2019 by 57%.
  • In addition to being ASEAN’s biggest healthcare stock and the largest constituent of the iEdge SG All Healthcare Index, Top Glove also emerged its position as the world’s largest manufacturer of nitrile gloves, in addition to being the world’s largest manufacturer of natural rubber gloves and surgical gloves.

Click here for the full results statement.



Riverstone Holdings (SGX:AP4)
  • While supported by current industry tailwinds, Riverstone continues to focus on internal initiatives such as adopting automation to improve productivity and reduce reliance on labour.
  • Its in-house R&D team continues to monitor industry trends closely and develop new products that will allow the Group to venture into untapped markets, such as the food processing, pharmaceutical and surgical glove segments.
  • For its cleanroom glove business, it continues to build on our reputation as a technological front-runner by delivering highly customised solutions and cutting-edge products to maintain its market-leading position.
  • Phase 6 of its expansion plan is on track to raise capacity by up to 1.4 billion to a total of 10.4 billion pieces of gloves per annum by 4Q FY2020, and will help to alleviate the current supply crunch.
    • The new Phases 7 to 9 are projected to grow capacity by up to 1.4 billion pieces a year to bring capacity to 14.0-15.0 billion pieces by FY2023.
  • Riverstone is positioning itself to capture future growth with the launch of its new three-year expansion plan at a new production site in Taiping.
  • With these initiatives in place, Riverstone has cultivated a business model that supports earnings resiliency and drives long-term sustainable growth.

Click here for the full results statement.  



UG Healthcare (SGX:41A)
  • Since early May, UG Healthcare has been operating at its optimum efficiency of 2.9 billion pieces of gloves per annum.
  • To cope with the higher demand, the earlier planned additional capacity of 300 million pieces of gloves per annum by end June 2021 will be brought forward to March 2021.
  • The intended additional capacity will be raised by 200 million pieces per annum to 500 million pieces per annum with the advancements in the design and technology of the production lines.
  • It is planning to expedite a further expansion in production capacity by another 1.2 billion pieces per annum, which will bring the Group’s installed production capacity to 4.6 billion pieces per annum by end June 2021 or the beginning of 1Q FY22 (end-September 2021).

Click here for the full results statement.







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












Stock / REIT Search

Advertisement

Advertisement